List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION provided by applicant Smoking remains the number one avoidable cause of death in the United States and costs the economy tens of billions of dollars every year Current therapies include nicotine replacement with a patch or gum inhibition of the dopamine system with bupropion and partial activation of the neuronal nicotinic acetylcholine receptor nAChR with varenicline Non ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Fully Independent Real Time Treatment Verification System for Radiotherapy

    SBC: SUN NUCLEAR CORP.            Topic: 102

    DESCRIPTION provided by applicant Modern day radiotherapy has developed in complexity to the degree that significant treatment errors are both difficult to detect and difficut to completely avoid In the current day radiotherapy department it is common to have a large number of patients being treated with Intensity Modulated Radiotherapy IMRT techniques When treating patients with these tec ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Process Chemistry of Largazole, a Marine HDAC Inhibitor with Anticancer Activity

    SBC: Oceanyx Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Significance Colorectal cancer CRC remains an unmet need and is a significant challenge to the healthcare system as one of the leading forms of cancer in the United States affecting an estimated people and causing an estimated deaths in Estimates of base case for the medical care costs for colorectal cancer in were $ billion a ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. RSK3 Anchoring Disruptor Therapy for Heart Failure

    SBC: ANCHORED RSK3 INHIBITORS, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Pathological cardiac remodeling including myocyte hypertrophy and apoptosis and myocardial interstitial fibrosis constitutes a common pathway to heart failure in disease Despite current pharmacologic therapy and other advances that attenuate remodeling mortality due to heart failure remains high New more effective therapeutic options are desperately neede ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical utility of serum biomarkers for the management of neonatal Hypoxic Ischemic Encephalopathy (HIE) on a point-of-care device

    SBC: BANYAN BIOMARKERS, INC.            Topic: NICHD

    DESCRIPTION provided by applicant Systemic asphyxia occurs in of births and can lead to hypoxic ischemic encephalopathy HIE Between and of neonates with HIE die or have permanent deficits Although hypothermia is the standard of care for HIE we cannot differentiate patients who respond to hypothermia from non responders The primary goal of this project is to conduct a proof ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. High Performance Seizure Monitoring and Alert System

    SBC: Optima Neuroscience, Inc.            Topic: 105

    DESCRIPTION provided by applicant Patients are frequently hospitalized for management of uncontrolled seizures due to epilepsy or acute neurological insults such as trauma stroke infections and a number of toxic and metabolic disorders However inpatient management of seizures is complicated by the fact that they occur intermittently and unpredictably and thus it i not infrequent that pati ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Novel piperazine tethered thiazole compounds as antimalarials

    SBC: Smart Biomolecules, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all av ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a synthetic antibody based on the HIV receptor and co-receptor that is optimized for highly efficient killing of HIV-infected cells by ADCC

    SBC: EMMUNE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Eliciting antibodies that neutralize human immunodeficiency virus type HIV by vaccination is a daunting challenge due to features of the HIV envelope glycoprotein Env that render it inherently resistant to antibody responses and the extraordinary antigenic diversity that has accrued since the beginning of the HIV pandemic To circumvent these form ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government